Everyone's favorite pharma that can rise x2 I'm sure you wil | 🚀 Robin Rocket

Everyone's favorite pharma that can rise x2 I'm sure you will appreciate this survey.

Esperion Therapeutics, Inc., $ESPR
Current price: $11.20
Target price: $20-25

Esperion Therapeutics, Inc. is a pharmaceutical company dedicated to the development and commercialization of affordable oral nestatin drugs for the treatment of patients with elevated low density lipoprotein (LDL) cholesterol.

Esperion recently reported mixed second quarter earnings with higher earnings per share and no revenue.

In the midst of the pandemic, Esperion launched two new drugs: Nexletol and Nexlizet.

The company showed that NEXLETOL and NEXLIZET had a good quarter, with net revenues growing 67% and prescriptions up 28%.

In 2026, the annual sales of the Nexletol franchise to treat millions of people worldwide who cannot control their cholesterol with statins are expected to reach $1.8 billion.

Not an investment recommendation